-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics publishes HARMONi-2 ivonescimab vs pembrolizumab quality-of-life presentation; median PFS rises to 11.1 months due to HR 0.51

Reuters·03/27/2026 16:25:49

Please log in to view news